Skip to main content

How to Launch Generics in Russia, when the RLD is approved!

How to Launch Generics in Russia, when the RLD is approved.

If the reference listed drug (RLD) is not available in Russia, launching a generic version can be a more complex process compared to countries where the RLD is already marketed. Here are some steps and considerations to keep in mind:

1. Market Research: 

Conduct thorough market research to understand the demand for the generic drug and potential competitors in the Russian market.

2. Regulatory Approval:

Seek approval from the Russian regulatory authority, the Ministry of Health of the Russian Federation, to market the generic drug. You will need to submit a comprehensive dossier containing safety, efficacy, quality, and manufacturing data, even if the RLD is not available in Russia.

3. Clinical Trials: 

In some cases, local clinical trials may be required to support the safety and efficacy claims of the generic drug.

4. Patent Considerations: 

Ensure that there are no patents or exclusivity rights that could hinder the launch of the generic drug in Russia. If there are relevant patents in other countries, consider international patent laws and potential legal challenges.

5. Importation: 

If the RLD is available in other countries, explore the possibility of importing the RLD to Russia and using it as a reference for bioequivalence studies. However, make sure to comply with all importation and customs regulations.

6. Licensing and Partnership: 

Consider collaborating with a local pharmaceutical company or distributor to navigate the Russian market and establish distribution channels.

7. Pricing and Reimbursement: 

Develop a pricing strategy that aligns with the local market and reimbursement policies.

8. Marketing and Sales: 

Develop a marketing plan tailored to the Russian market and its specific requirements.

9. Quality Assurance: 

Ensure the generic drug manufacturing process complies with Good Manufacturing Practices (GMP) and other relevant quality standards.

Launching a generic drug in a market where the RLD is not available can present both opportunities and challenges. It is essential to work closely with local regulatory experts, legal advisors, and distribution partners to navigate the process successfully and comply with all applicable laws and regulations.

Comments

Post a Comment

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em
1 comment
Read more

DoE - Doctrine of Equivalents

The Doctrine of Equivalents is a legal principle that is relevant to patent law, particularly in the United States, and it helps protect inventors' rights even when minor changes or substitutions have been made to a patented invention.  When an inventor applies for a patent, the claims in the patent document define the scope of protection for the invention. These claims outline the specific elements or features of the invention that are considered unique and non-obvious. If another party copies or uses the patented invention without permission, it may be considered infringement. However, in some cases, the accused infringer may make slight modifications to the invention that fall outside the literal scope of the patented claims. The Doctrine of Equivalents comes into play here. It allows the patent holder to assert that the accused infringer's modified version is still equivalent to the patented invention and, therefore, falls within the scope of the patent protection. For the
Post a Comment
Read more

Competitive Landscape for Pharmaceutical Generic products.

Creating a competitive landscape for a pharmaceutical generic product involves analyzing the market and identifying key players, their strengths, weaknesses, and market positioning. Here's a simplified outline: **Competitive Landscape Analysis for Pharmaceutical Generic Product:** 1. **Market Overview:**    - Size of the pharmaceutical generic product market.    - Growth trends and forecasts.    - Regulatory environment and barriers to entry. 2. **Key Players:**    - List the major pharmaceutical companies producing the generic product.    - Include both global and regional players. 3. **Market Share:**    - Percentage of market share held by each major player.    - Trends in market share changes over time. 4. **Product Portfolio:**    - Types of generic products offered by each player.    - Variations in strengths, dosage forms, and delivery methods. 5. ** Competitive Advantage :**    - Identify unique selling points of each player's products.    - Cost advantages, manufacturi
Post a Comment
Read more